Overview

The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
0
Participant gender:
Female
Summary
This study aims at evaluating and comparing the anti-tumor effects of metformin and statins (hydroxyl-methyl-glutaryl-CoA reductase inhibitors) in patients with non-metastatic breast cancer (stage I, II, & III).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tanta University
Treatments:
Atorvastatin
Metformin
Criteria
Inclusion Criteria:

- Patients with radiologically and histologically (biopsy) confirmed diagnosis of breast
cancer and with stage I, II, and stage III breast cancer according to the American
Joint Committee on Cancer (TNM staging system of breast cancer).

- Patients with no contraindication for chemotherapy, metformin, or statins

- Females aged ≥ 18 years old

- Performance status < 2 according to the Eastern Cooperative Oncology Group (ECOG)
score

Exclusion Criteria:

- Patients with metastatic breast cancer (stage IV)

- Pregnant or lactating women.

- Patients with hepatic or renal impairment.

- Patients with myopathy.

- Patients with any condition predispose to acidosis (COPD, heart failure, ….)

- Patients who had dementia, mental retarded, and any psychiatric condition that would
prohibit the understanding or signing of informed consent.